At the time of writing, Mersana Therapeutics Inc [MRSN] stock is trading at $4.45, up 5.45%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MRSN shares have gain 3.49% over the last week, with a monthly amount drifted -22.61%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 28, February 2024, Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results. In a post published today on Yahoo Finance, Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660; expect to initiate tumor-specific expansion cohorts in the second quarter of 2024 and announce initial clinical data in mid-2024.
From an analyst’s perspective:
Mersana Therapeutics Inc [NASDAQ: MRSN] stock has seen the most recent analyst activity on March 19, 2024, when JP Morgan upgraded its rating to a Neutral but kept the price target unchanged to $5 for it. Previously, Wedbush upgraded its rating to Outperform on February 29, 2024, and elevated its price target to $7. On February 29, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $7 on the stock. BTIG Research upgraded its rating to a Buy but stick to its price target of $6 on February 29, 2024. Citigroup upgraded its rating to a Buy and raised its price target to $5 on December 04, 2023. Robert W. Baird downgraded its rating to Neutral for this stock on July 28, 2023, and downed its price target to $1. In a note dated July 27, 2023, Wedbush downgraded an Neutral rating on this stock.
For the past year, the stock price of Mersana Therapeutics Inc fluctuated between $0.80 and $9.62. Mersana Therapeutics Inc [NASDAQ: MRSN] shares were valued at $4.45 at the most recent close of the market.
Analyzing the MRSN fundamentals
According to Mersana Therapeutics Inc [NASDAQ:MRSN], the company’s sales were 36.85M for trailing twelve months, which represents an -27.14% plunge. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -4.67%, Pretax Profit Margin comes in at -4.66%, and Net Profit Margin reading is -4.68%. To continue investigating profitability, this company’s Return on Assets is posted at -0.76, Equity is -2.84 and Total Capital is -1.06. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.78.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.16 points at the first support level, and at 3.87 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.60, and for the 2nd resistance point, it is at 4.75.
Mersana Therapeutics Inc [MRSN] reported earnings per share of -$0.16 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.16/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.35 per share as compared to estimates of -$0.36 per share, a difference of $0.01 representing a surprise of 2.80%.
Ratios To Look Out For
It is important to note that Mersana Therapeutics Inc [NASDAQ:MRSN] has a current ratio of 3.36. As well, the Quick Ratio is 3.36, while the Cash Ratio is 2.74. Considering the valuation of this stock, the price to sales ratio is 14.65, the price to book ratio is 14.56.
Transactions by insiders
Recent insider trading involved Protopapas Anna, Director, that happened on Jan 16 ’24 when 29399.0 shares were sold. SVP, Chief Sci.&Tech. Officer, Lowinger Timothy B completed a deal on Jan 16 ’24 to sell 10409.0 shares. Meanwhile, SVP, COO & CFO DeSchuytner Brian sold 9327.0 shares on Jan 16 ’24.
